Blondy Kayembe-Mulumba

Dr. Blondy Kayembe-Mulumba

INSERM, BPH, U1219, University of Bordeaux, Bordeaux, Nouvelle-Aquitaine, France
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Blondy Kayembe-MulumbaBlondy Kayembe-Mulumba
Blondy Kayembe-Mulumba
ANAnderson Kouabenan N’gattia
Anderson Kouabenan N’gattia
MBMarie Roseline Darnycka BELIZAIRE
Marie Roseline Darnycka BELIZAIRE
The emergence of high-threat pathogens—such as Ebola, Lassa fever, and most recently SARS-CoV-2—has highlighted critical weaknesses in global surveillance systems, particularly in resource-limited settings where many zoonotic spillovers originate. Despite the World Health Organization’s (WHO) prioritization of these diseases for research and development (R&D), the current surveillance infrastructures in these regions remain under-resourced, fragmented, and often reactive rather than anticipatory. This narrative review explored the literature and structured relevant findings in three key dimensions: (i) the structural and operational limitations of existing surveillance systems for the WHO priority diseases in resource-limited settings including challenges in data integration, laboratory capacity, workforce, and community engagement; (ii) how these surveillance gaps could delay detection and hinder the response to future emerging threats, particularly a hypothetical but inevitable Disease X; and (iii) innovative and context-adapted strategies to strengthen epidemic intelligence including integrated One Health surveillance, digital and genomic tools, participatory approaches, and regional data-sharing mechanisms. We argue that building agile, equity-centered, and decentralized surveillance systems is not only essential for managing known threats, but also foundational to the early detection and rapid containment of the next public health emergency in resource-limited settings. This review uniquely frames surveillance limitations in resource-limited settings as a global security concern and outlines context-adapted, equity-centered innovations to strengthen epidemic intelligence in preparation for Disease X.

15 July 2025 in Ophthalmology Science
Verified
Journal Article
Open access
Blondy Kayembe-MulumbaBlondy Kayembe-Mulumba
Blondy Kayembe-Mulumba
KLKaren Leffondré
Karen Leffondré
BMBénédicte MJ Merle
Bénédicte MJ Merle
JKJean-François Korobelnik
Jean-François Korobelnik
CHCatherine Helmer
Catherine Helmer
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
Long-term blood pressure variability (BPV) has emerged as a risk factor for various health problems, including eye diseases, independent of blood pressure (BP) levels. Yet, its role in age-related macular degeneration (AMD) progression remains unknown. This study aimed to assess associations between long-term BPV and the risk of AMD. Prospective analysis of 14-year data from the ALIENOR (Antioxydants, LIpides Essentiels, Nutrition et maladies OculaiRes) study, a French longitudinal population-based cohort study (2006-2020). The ALIENOR study included 963 participants aged ≥73 years from the Three-City (3C) study in Bordeaux, for an ophthalmic follow-up. Systolic BPV (SBPV), diastolic BPV (DBPV), and pulse pressure variability (PPV) were determined as the standard deviation of available BP measurements in 3C visits (1999-2017). Age-related macular degeneration was assessed using retinal color photographs and OCT imaging every 2 years from 2006 to 2020. Shared random effects joint models fitted BPV current values and quantified their effect on AMD onset. The implemented Bayesian approach yielded the mean of adjusted posterior hazard ratios of AMD and their 95% credibility intervals (CrIs). Of the 692 (median age: 79.0 years; 63.5% female) and 475 (median age: 78.5 years; 61.1% female) at-risk participants, 10% and 36% developed advanced and intermediate AMD, respectively. The hazard of advanced AMD was significantly increased by 54% for a 5-mmHg increase in DBPV (adjusted hazard ratio [aHR]: 1.54, 95% CrI: 1.02-2.44), whereas statistical significance was not reached for a 5-mmHg increase in SBPV (aHR: 1.20, 95% CrI: 0.96-1.51) and PPV (aHR: 1.17, 95% CrI: 0.88-1.54). Conversely, BPV was not significantly associated with intermediate AMD (aHR: 0.96, 95% CrI: 0.83-1.11; aHR: 0.96, 95% CrI: 0.71-1.30; and aHR: 0.92, 95% CrI: 0.77-1.09; for a 5-mmHg increase in SBPV, DBPV, and PPV, respectively). This study suggested that long-term variability in BP may be associated with an increased risk of advanced AMD, particularly for DBP. These findings underscore the need for further research to confirm this association, explore the underlying mechanisms, and propose potential interventions that could mitigate this risk. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

2 January 2025 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
Blondy Kayembe-MulumbaBlondy Kayembe-Mulumba
Blondy Kayembe-Mulumba
KLKaren Leffondré
Karen Leffondré
PJPierre Joly
Pierre Joly
MDMarie-Noëlle Delyfer
Marie-Noëlle Delyfer
CDCécile Delcourt
Cécile Delcourt

15 October 2025 in AJE Advances: Research in Epidemiology
Verified
Journal Article
Open access
Blondy Kayembe-MulumbaBlondy Kayembe-Mulumba
Blondy Kayembe-Mulumba
PLPetra P Larsen
Petra P Larsen
KLKaren Leffondré
Karen Leffondré
PJPierre Joly
Pierre Joly
JKJean-François Korobelnik
Jean-François Korobelnik
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
Elevated high-density lipoprotein cholesterol (HDL-C) has been regularly associated with age-related macular degeneration (AMD). However, this association could be due to longer life expectancy in subjects with high HDL-C. Thus, we assessed the association of HDL-C with incident AMD, using an illness-death model (IDM) for interval-censored data to account for death as a competing risk. The ALIENOR study included 963 participants aged 73 and older from Bordeaux, France. Plasma HDL-C was measured at baseline. AMD was assessed repeatedly using multimodal retinal imaging (2006-2020). The IDM estimated adjusted hazard ratios (aHR [95% confidence interval]) of incident AMD, and mortality in AMD-free and AMD-affected individuals. Analyzed samples included individuals at risk of intermediate (n = 472) and advanced (n = 690) AMD. HDL-C (1-standard deviation increase) was not significantly associated with the hazard of intermediate (aHR: 1.15 [0.97-1.37]) and advanced (aHR: 1.16 [0.90-1.49]) AMD onset. Additionally, in the intermediate AMD analysis, HDL-C was significantly associated with lower mortality in AMD-free (aHR: 0.74 [0.56-0.97]) and higher mortality in AMD-affected individuals (aHR: 1.55 [1.17-2.05]). Future research should leverage robust statistical methods, such as the IDM, to mitigate survival bias and enhance the accuracy of hazard ratios estimation to confirm our findings.

18 December 2025 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
Blondy Kayembe-MulumbaBlondy Kayembe-Mulumba
Blondy Kayembe-Mulumba
KLKaren Leffondré
Karen Leffondré
PLPetra P. Larsen
Petra P. Larsen
ÉHÉmilie Hucteau
Émilie Hucteau
JKJean-François Korobelnik
Jean-François Korobelnik
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer

28 May 2026 in Current Eye Research
Verified
Journal Article
Closed access
Blondy Kayembe-MulumbaBlondy Kayembe-Mulumba
Blondy Kayembe-Mulumba
CDCécile Delcourt
Cécile Delcourt
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
Epidemiological studies yielded conflicting results regarding the relationship between cardiometabolic factors and age-related macular degeneration (AMD). However, the methodological characteristics of these studies, which may partly explain this controversy, are not currently addressed. This narrative review aimed to examine current evidence between the six most studied cardiometabolic factors and AMD, focusing on identifying key methodological shortcomings and discussing analytical approaches currently available to address them. We conducted a rigorous, nonsystematic literature search using targeted MeSH terms and keywords in MEDLINE (PubMed), EMBASE, Web of Science and Scopus, with no language restrictions, up to June 2025. We identified and reviewed epidemiological (cross-sectional, case-control, cohort) studies reporting original data on the six targeted cardiometabolic factors: blood pressure, antihypertensive medications, lipid levels, lipid-lowering medications, diabetes mellitus and antidiabetic treatments. A quantitative synthesis of studies was conducted to describe their methodological characteristics and reported associations. Across the 116 reviewed associations, prospective cohorts (41%) and cross-sectional designs (37%) predominated. Most originated from America (35%) and Europe (32%). Lipids (21%) and lipid-lowering agents (20%) were the most frequently studied exposures, while advanced AMD was the predominant outcome (56%). Logistic regression was the main analytic approach (70%), and association conclusions were most often null (42%), followed by increased (36%) and decreased (22%) risk. The most common methodological limitations included cross-sectional study designs, static modeling of dynamic exposures, unaddressed interval censoring, not controlling for confounding by indication, and unstandardized selection of confounders, which are likely to bias the reported associations. Future studies should prioritize robust methodological frameworks, including longitudinal designs, survival bias mitigation, standardized and repeated exposure assessments, distinction between AMD subtypes, propensity scores for medications use, and advanced causal inference techniques wherever feasible. Such an effort is foundational to strengthening the validity and reproducibility of findings linking cardiometabolic factors to AMD, thereby improving AMD prevention strategies.